These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 14965330)

  • 21. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Future drug targets for Parkinson's disease].
    Hirsch EC
    Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective and Neurotherapeutic Effects of Tetrahedral Framework Nucleic Acids on Parkinson's Disease
    Cui W; Zhan Y; Shao X; Fu W; Xiao D; Zhu J; Qin X; Zhang T; Zhang M; Zhou Y; Lin Y
    ACS Appl Mater Interfaces; 2019 Sep; 11(36):32787-32797. PubMed ID: 31424187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism.
    Park G; Park YJ; Yang HO; Oh MS
    Pharmacol Biochem Behav; 2013 Mar; 104():163-8. PubMed ID: 23369986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of endoplasmic reticulum stress in Parkinson's disease.
    Tsujii S; Ishisaka M; Hara H
    Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of treatment of depression in assuring the most efficacious management of Parkinson's disease.
    Kaiser HE; Bodey B; Bodey B
    In Vivo; 2000; 14(3):457-62. PubMed ID: 10904882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
    Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
    Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease.
    Chen Y; Zhang Y; Li L; Hölscher C
    Eur J Pharmacol; 2015 Dec; 768():21-7. PubMed ID: 26409043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?].
    Storch A
    Nervenarzt; 2007 Dec; 78(12):1378-82. PubMed ID: 17508194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's Disease.
    Miyazaki I; Asanuma M
    Curr Med Chem; 2016; 23(7):686-700. PubMed ID: 26795196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.
    Wilms H; Zecca L; Rosenstiel P; Sievers J; Deuschl G; Lucius R
    Curr Pharm Des; 2007; 13(18):1925-8. PubMed ID: 17584117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
    Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
    Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatments of Parkinson disease: circa 2003.
    Shults CW
    Arch Neurol; 2003 Dec; 60(12):1680-4. PubMed ID: 14676041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minocycline enhances MPTP toxicity to dopaminergic neurons.
    Yang L; Sugama S; Chirichigno JW; Gregorio J; Lorenzl S; Shin DH; Browne SE; Shimizu Y; Joh TH; Beal MF; Albers DS
    J Neurosci Res; 2003 Oct; 74(2):278-85. PubMed ID: 14515357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease.
    Miyazaki I; Asanuma M
    Curr Pharm Des; 2017; 23(33):4936-4947. PubMed ID: 28699520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minocycline inhibits ICAD degradation and the NF-κB activation induced by 6-OHDA in PC12 cells.
    Jiang BP; Le L; Xu LJ; Xiao PG
    Brain Res; 2014 Oct; 1586():1-11. PubMed ID: 25195972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease.
    Kim M; Cho KH; Shin MS; Lee JM; Cho HS; Kim CJ; Shin DH; Yang HJ
    Int J Mol Med; 2014 Apr; 33(4):870-8. PubMed ID: 24535622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
    Grünblatt E; Mandel S; Youdim MB
    Ann N Y Acad Sci; 2000; 899():262-73. PubMed ID: 10863545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.